中文

← All funding rounds

Basecamp Research

EuropeBiology data and toolsLondon (labs in Cambridge, MA), United KingdomFounded 2019Private

Website · basecamp-research.com ↗

Collects genetic data from nature through partnerships in over 30 countries, trains its EDEN models on it, and now uses them to design therapies, starting with in vivo cell therapy.

Disclosed total$220M
Rounds on record3
Latest round$140MSeries C · 2026-09-23
Last stated valuationNone stated
Investors named22
Research on record1highest level 4 · Tested in the physical world

Money and evidence

Moneyeach round in US dollars; ≈ converted at its date2023202420252026$20M$60M$140MEvidencelevel of each research entry12345
Closed roundResearch entry, at its level

Latest round, Series C, 2026-09-23: the record then held 1 research entry, highest level 4. The first research entry is dated 2026-01-12; the highest level so far is 4 (Tested in the physical world).

Rounds and research, on one timeline

  1. 2026-09-23Series C
    Round

    $140M

    For: training new EDEN models and moving AI-designed therapies toward the clinic

    Models and platformToward the clinic

    Read from the corrected release.

    Lead · S32 ✓Menlo Ventures' Anthology FundNVIDIA ✓NATO Innovation Fund ✓Sovereign AITrue Ventures ✓Redalpine ✓Catalio Capital ManagementEuropean Tech CollectiveFirebrand River CapitalInception Fund ✓King PhilanthropiesPostScriptumThe Rockefeller FoundationSingular ✓

    On the deal: André Hoffmann (Angel investor); Andy Conrad (General Partner, S32, joins the board)

    The investor's own page says · NATO Innovation Fund: Series C 2026

    The investor's own page says · Redalpine: fund RAC VII

    By this date the record held 1 research entry, highest level 4

    Announced by the company · prnewswire.com ↗On the timeline →

  2. 2026-01-12
    Research

    Level 4 · Tested in the physical world

    Basecamp Research's EDEN model designs enzymes that insert large DNA at a chosen spot in the human genome, and half of them worked in human cells

    Putting a whole gene into a genome usually means a virus or a cut in the DNA, which caps the payload and brings safety risk. A recombinase swaps DNA in at a site it recognises instead, but each site has needed its own enzyme, and finding one was a project in itself. Here 30 bases of a target were enough to get working enzymes at every site the paper reports testing. If that holds up outside the company, the enzyme is designed for the site rather than searched for in nature.

    Timeline entry →biorxiv.org ↗

  3. 2024-10-09Series B
    Round

    $60M

    For: expanding its biological dataset and building more capable models

    Data generationModels and platform

    Brought total raised to $85M.

    Lead · Singular ✓S32 ✓redalpine ✓André HoffmannFeike SijbesmaPaul PolmanTrue Ventures ✓Hummingbird Ventures ✓

    On the deal: André Hoffmann (Angel investor); Feike Sijbesma (Angel investor); Paul Polman (Angel investor); Raffi Kamber (General Partner, Singular)

    Announced by the company · tech.eu ↗

  4. 2022-12Series A
    Round

    $20M

    For: growing the team, validating internal products, and building protein products

    HiringCommercial roll-out

    Brought total raised to $30M; co-founder Oliver Vince quoted.

    Lead · Systemiq VenturesValoBlue Horizon ✓True Ventures ✓Hummingbird Ventures ✓

    The investor's own page says · Blue Horizon: Seed

    Announced by the company · tech.eu ↗

Research entries are the timeline's graded entries that name this company. A level grades one claim, not the company, and a blank can mean the record has not caught up rather than that nothing was published.

See these rounds in the table →

On the investors' own sites

Investors that name this company on their own site, in a portfolio or their own announcement. A ✓ in a round marks the same investor.

Its investors also backed

Other companies on this page whose rounds name the same investor.